CUSABIO has expanded its flexible recombinant antibody expression service for AI-driven antibody discovery, supporting projects from 1 to 1,000+ sequences with 3 mL, 10 mL and 20 mL expression options. Optional ELISA, SPR/LSPR and BLI validation enables teams to adjust wet-lab support from round to round.
HOUSTON, Sept. 23, 2026 /PRNewswire-PRWeb/ -- CUSABIO today announced an expanded flexible recombinant antibody expression service designed to support the changing experimental needs of AI-driven antibody discovery. The service allows research teams to configure projects from a single antibody sequence to 1,000+ candidates, select 3 mL, 10 mL or 20 mL expression scales, and add binding or activity validation according to the needs of each discovery round.
Researchers can learn more about CUSABIO's Flexible Antibody Expression for AI Discovery and configure projects based on sequence count, expression scale and validation requirements.
AI-driven antibody discovery is inherently iterative. One design round may generate only a handful of high-confidence candidates, while subsequent optimization or screening rounds may expand to dozens, hundreds or more. Material requirements and expe...